Head to Head Survey: Kalaris Therapeutics (NASDAQ:KLRS) versus GRAIL (NASDAQ:GRAL)

Kalaris Therapeutics (NASDAQ:KLRS) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Kalaris Therapeutics and GRAIL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
GRAIL	-236.95%	-15.88%	-14.02%

Institutional and Insider Ownership

66.0% of Kalaris Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Kalaris Therapeutics and GRAIL, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1	0	6	0	2.71
GRAIL	1	5	4	0	2.30

Kalaris Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 380.77%. GRAIL has a consensus price target of $67.78, indicating a potential downside of 15.64%. Given Kalaris Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Kalaris Therapeutics is more favorable than GRAIL.

Earnings and Valuation

This table compares Kalaris Therapeutics and GRAIL”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44 million	($2.02)	-1.93
GRAIL	$147.17 million	24.39	-$408.35 million	($9.75)	-8.24

Kalaris Therapeutics has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Kalaris Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, GRAIL has a beta of 3.25, meaning that its share price is 225% more volatile than the S&P 500.

Summary

Kalaris Therapeutics beats GRAIL on 9 of the 13 factors compared between the two stocks.

About Kalaris Therapeutics

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

About GRAIL

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.